Search PubMed⌕ Search

Biomedical subjects

N Nakamizo

Publications and source records attributed to N Nakamizo.

At least 37 records · Page 2Linked to original sources

Effects of the new calcium antagonist benidipine hydrochloride on cardiohemodynamics in anesthetized dogs.

The effects of (+/-)-(R*)-2,6-dimethyl-4-(m-nitro-phenyl)-1,4-dihydropyridine -3,5-dicarboxylic acid (R*)-1-benzyl-3-piperidinylester, methylester hydrochloride (benidipine hydrochloride, KW-3049) on the cardiohemodynamics were investigated in open-chest, anesthetized dogs, in comparison with those of nifedipine. When KW-3049 at a dose of 3 micrograms/kg was intravenously administered, hypotensive action (delta dBP = -20 mmHg) with a peak attained 3 to 5 min after the administration was observed and its action lasted for 2 h or more. Simultaneously, a slight decrease of heart rate and continuous increases of LV max dp/dt and cardiac output were recognized. At the administration with 10 micrograms/kg i.v., hypotensive action (delta dBP = -35 mmHg) with a peak 3 min after the administration appeared and continued for 3 h or more. At this time, continuous decrease of heart rate by about 18% and continuous increase of cardiac output were observed. The LV max dp/dt transiently decreased and then turned to increase, and the cardiac work was continuously decreased. When nifedipine at doses of 10 or 50 micrograms/kg was intravenously administered, hypotensive action (delta dBP = -31 and -52 mmHg) with a peak attained 1 min after the administration was observed and its action rapidly began to recover. At the administration with 50 micrograms/kg i.v., the heart rate was slightly decreased (10%). The LV max dp/dt was transiently reduced by 18% at 10 micrograms/kg i.v. and by 45% at 50 micrograms/kg i.v., respectively, and the augmented cardiac output lasted for 30 to 60 min. At the administration of 50 micrograms/kg i.v., cardiac work was continuously decreased.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Beneficial effects of the new calcium antagonist benidipine hydrochloride on myocardial dysfunction following coronary occlusion and reperfusion in anesthetized dogs.

The protective effect of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1, 4-dihydropyridine-3,5-dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) on ischemic myocardium was examined comparing with that of nifedipine in anesthetized dogs subjected to a brief (10 min) coronary artery occlusion and reperfusion (2h). Occlusion of left anterior descending coronary artery elicited elevation of ST-segment and T-wave of epicardial ECG in the ischemic area. Regional myocardial contractile force in this area was depressed throughout the reperfusion period as well as during coronary occlusion period. LV max dp/dt, stroke volume and cardiac output tended to be reduced. In the dogs pretreated with 10 micrograms/kg of KW-3049 (i.v.) and 50 micrograms/kg of nifedipine (i.v.), both of which lowered the blood pressure to the same extent, elevation of ST-segment and T-wave was inhibited, and the prevention of irreversible depression of regional myocardial contraction observed at reperfusion periods was slightly more prominent in KW-3049 administration group. Stroke volume and cardiac output in both KW-3049 and nifedipine administration groups were maintained at higher levels than those in control group throughout coronary occlusion and the following reperfusion periods. LV max dp/dt of KW-3049 administration group was kept higher than that of the control group, while the value of the nifedipine administration group changed as that of the control group. These results demonstrate that KW-3049 as well as nifedipine exert protective effects on ischemic myocardium induced by coronary occlusion and reperfusion.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Pharmacological actions of benidipine hydrochloride in several isolated smooth muscles and myocardium.

Using various isolated smooth muscles and myocardium, the calcium antagonistic effect of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)- 1,4-dihydropyridine-3,5-dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049), and its specificity were examined. Furthermore, the in vitro duration of action and the antispasmodic actions in coronary arteries were investigated in comparison with those of nifedipine, verapamil and diltiazem. 1. Ca antagonisms of KW-3049 When the Ca antagonistic effect of KW-3049 was investigated, for which the contractile responses to KCl in isolated mesenteric arteries in rabbits were taken as an indicator, the activity of KW-3049 was of about the same degree as nifedipine and approx. 30 times greater than those of verapamil and diltiazem. On the other hand, the negative inotropic action in isolated atria in rabbits was weaker than that of nifedipine. 2. Influences on responses to various agonists From the investigations using various isolated organs, it was evident that KW-3049 had neither agonistic nor antagonistic actions or very weak actions on the following receptors: alpha 1, alpha 2, beta 1, beta 2, H1, H2, muscarinic acetylcholine, 5HT2, angiotensin II, and prostaglandin F2 alpha. 3. Duration of in vitro actions Inhibitory actions of KW-3049 on 55 mmol/l-induced contractions in isolated mesenteric arteries in rabbits persisted even 180 min after the removal of drug solution and the repeated wash-out of tissues. On the other hand, those of nifedipine, verapamil and diltiazem disappeared within 60 to 120 min.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Gas chromatographic method for the quantification of the new calcium antagonist benidipine hydrochloride in plasma using electron capture detection.

A gas chromatographic assay procedure was developed for measuring subnanogram order concentrations of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) in plasma. KW-3049 yielded the oxidation product partially during gas chromatography. To avoid decomposition, KW-3049 was oxidized in advance by nitrogen dioxide, extracted by diethylether under alkaline condition, chromatographed on the OV-1 column and measured using electron capture detector.

Animals↗

Sensitive radioreceptor assay of the calcium antagonist benidipine hydrochloride in plasma and urine.

Plasma and urinary concentrations of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) were measured by the radioreceptor assay using 3H-nitrendipine and rat cardiac membrane receptor. After methanol deproteinization and ethyl ether extraction under alkaline conditions as pretreatment, the detection limit for KW-3049 in plasma was 0.2 ng/ml using 0.5 ml of sample. For the urine, 0.05 ml of urine sample was directly added to the assay system, and detection limit of drug was 1 ng/ml. The cross-reactivity of the presumable metabolites was 1% or less of the unchanged drug. This radioreceptor technique was applied to pharmacokinetic studies and useful for monitoring the drug after therapeutic dosing.

Animals↗

Determination of the calcium antagonist benidipine hydrochloride in plasma by sensitive radioimmunoassay.

A sensitive radioimmunoassay of the 1,4-dihydropyridine calcium channel blocker (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) has been developed. Antiserum against KW-3049 was produced in rabbits by immunization with an immunogen prepared by conjugating a derivative of KW-3049 to bovine serum albumin. This antiserum was found to specifically bind to [3H]-KW 3049, while the recognition to [3H]-nitrendipine, another well-known dihydropyridine calcium channel blocker, was less pronounced. With the antiserum, [3H]-KW-3049 and dextran coated charcoal, this radioimmunoassay could detect 39 approximately equal to 500 pg/tube of KW-3049 in a buffer system, and 156 to 5000 pg/ml of KW-3049 in plasma by using 0.5 ml of the plasma which was pretreated with MeOH for deproteinization and extracted with diethyl ether under alkaline condition. To assess the specificity of the radioimmunoassay, the inhibition of [3H]-KW-3049 binding to the antiserum by the presumable metabolites was examined. Though three of these presumable metabolites could slightly inhibit the binding of [3H]-KW-3049, they were not detected in rat and dog plasma at 0.5 h after oral administration of KW-3049. Plasma levels of KW-3049 in rats receiving a single oral dose (1 mg/kg) determined by the radioimmunoassay show good agreement with those obtained by gas chromotography.

Animals↗

Absorption, distribution and excretion after oral administration of 14C-benidipine hydrochloride in rats and dogs.

(+/-)-(R*)-2,6-Dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5- dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) has been developed as antihypertensive and antianginal agent. The absorption, distribution and excretion were investigated after single oral administration of 14C-labeled KW-3049 using Wistar rats and beagle dogs. The results were summarized as follows: 1. After oral administration of 14C-KW-3049 to rats, the plasma radioactivity reached the maximum at 0.5 h, showed the second peak at 4 h and decreased biphasically with the biological half-lives of about 6 h and 38 h. 2. After oral administration of 14C-KW-3049 to dogs, the plasma radioactivity reached the maximum at 1 h and decreased biphasically with the biological half-lives of about 2 h and 25 h. 3. After oral administration to rats and dogs, the excretion of the radioactivity in feces and urine during 72 h (rats) and 96 h (dogs) were 74% and 19%, 66% and 25%, respectively. The radioactivity excreted in the bile was 34% during 48 h and was followed by partial reabsorption from the gastrointestinal tract. 4. High radioactivities were observed in the digestive organs, mesenteric lymphnodes, liver, pancreas, urinary bladder, fat tissue, kidney and spleen after oral administration to rats.

Administration, Oral↗

Absorption, distribution and excretion of 14C-benidipine hydrochloride after repeated administration to rats.

The absorption, distribution and excretion of (+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine-3,5-dicarb oxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) were studied after repeated doses to rats. The results were summarized as follows: 1. After oral repeated administration once a day for 3 weeks, the radioactivities in blood and tissues increased up to the 14th day, and thereafter they tended to show the steady state. 2. The radioactivity in the tissues at 1 h after last dosing was compared with that at 1 h after single administration. Both tissue distribution patterns were not markedly different, but the concentrations in the liver, testicles, skin and descending aorta significantly increased, showing approximately the 2-fold radioactivities. 3. The radioactivities were excreted in the urine (6%) and feces (88%). The excretion of radioactivity in urine and feces did not change markedly during the repeated administration period.

Administration, Oral↗

Pharmacokinetic study of benidipine hydrochloride in rats and dogs.

(+/-) - (R*) - 2,6-Dimethyl-4-(m-nitrophenyl)-1,4-dihydropyridine - 3, 5-dicarboxylic acid (R*)-1-benzyl-3-piperidinyl ester, methyl ester hydrochloride (benidipine hydrochloride, KW-3049) is presently under development as an anti-hypertensive and antianginal agent. A pharmacokinetic study in rat and dog after oral and intravenous administrations revealed that KW-3049 was rapidly absorbed from the gastrointestinal tract, distributed into tissues moderately and comparatively quickly eliminated. After oral administration, non-linearity of bioavailability with increment of doses was observed in both rat and dog. Female and male rats showed similar drug disposition after intravenous administration. Oxidation product of KW-3049 dihydropyridine ring was also measured in some plasma samples. The concentration rates of its pyridine metabolite accounted for 0 to 30% and 0 to 23% of the combined concentration of KW-3049 plus the pyridine metabolite in rat and dog.

Administration, Oral↗

Identification of benidipine hydrochloride metabolites in rats and dogs.

A study of the metabolism of [14C]-(+/-)-(R*)-2,6-dimethyl-4-(m-nitrophenyl)- 1,4-dihydropyridine-3, 5- dicarboxylic acid (R*)-1-benzyl-3-piperdidinyl ester, methyl ester hydrochloride (14C-benidipine hydrochloride, 14C-KW-3049) revealed as major metabolic pathways oxidative N-dealkylation, hydrolysis of the ester moiety, dehydrogenation of the 1,4-dihydropyridine ring, hydroxylation of the methyl group and decarboxylation in rat and dog. Rat and dog showed similar metabolic pathways, but some quantitative differences were found between rat and dog.

Animals↗

Generation of a new monoclonal antibody and its application for determination and purification of biologically active human gamma-interferon.

Three monoclonal antibodies (MAbs) were raised against recombinant human gamma-interferon (rHuIFN-gamma). They were specific for rHuIFN-gamma and recognized parts of the molecule other than both terminal regions. Among these MAbs, only KM48 has an ability to neutralize the antiviral activity of rHuIFN-gamma. Using KM48 in combination with polyclonal antibodies, we have developed a double-sandwich enzyme immunoassay (ELISA). This ELISA preferentially detects the biologically active form of rHuIFN-gamma, because after treatment with 1 N HCl or 0.2% SDS, or at 95 degrees C, the reactivity in the ELISA and the biological activity determined by cytopathic effect (CPE) assay decrease in parallel. In addition, the ELISA recognizes both natural and rHuIFN-gamma with almost the same sensitivity. Therefore, the ELISA is useful for detecting the biologically active conformation of rHuIFN-gamma, and possibly may be useful in both industrial production and clinical studies. rHuIFN-gamma molecules bind specifically to the immunoaffinity column using the MAb KM48 as ligands. After elution with 7 M Urea/1 M NaCl, the rHuIFN-gamma can be renatured in phosphate-buffered saline with high recovery. Thus, the column provides simple one-step purification of biologically active rHuIFN-gamma.

Animals↗

Different kinetics of antiviral and anticellular activities between human recombinant and natural interferon-gamma arising from different receptor-binding properties.

Human recombinant interferon-gamma (ReIFN-gamma) and human natural interferon-gamma (IFN-gamma) showed significant differences in antiviral and anticellular activities. Namely, ReIFN-gamma exhibited antiviral activity against Sindbis virus and anticellular activity against HeLa S3 cells at significantly lower concentrations as compared with IFN-gamma at short exposure times of between 1 and 4 hr. This difference of activities was explicable in terms of different binding activities of the two IFNs to the receptors. The binding of 125I-ReIFN-gamma to the receptors was competitively decreased in a dose dependent manner by unlabeled ReIFN-gamma, whereas the competition by unlabeled IFN-gamma was significantly weaker. The results of pretreatment of the cells with unlabeled ReIFN-gamma or IFN-gamma suggested that the binding of IFN-gamma to the receptors was slower than that of ReIFN-gamma. ReIFN-gamma and IFN-gamma exhibited greater colony formation-inhibitory activity against HeLa S3 cells, as compared with IFN-alpha or ReIFN-beta. ReIFN-gamma also inhibited DNA, RNA and protein syntheses of HeLa S3 cells more potently than ReIFN-beta. However, the 2'-5' oligoadenylate (2'-5' A) synthetase activity in ReIFN-gamma-treated cells was significantly lower than that in ReIFN-beta-treated cells, suggesting that 2'-5' A synthetase does not play a major role in the anticellular activity of ReIFN-gamma, at least against HeLa S3 cells.

2',5'-Oligoadenylate Synthetase↗

Involvement of disulfide-sulfhydryl interaction in anti-platelet actions of KF4939.

We studied on the role of an intramolecular disulfide bond of KF4939 in its anti-platelet actions by using rabbit platelets. The inhibitions of aggregation of platelet-rich plasma (PRP) and washed platelets, and of malondialdehyde production in thrombin-stimulated platelets by KF4939 were counteracted by pretreatment with sulfhydryl compounds, glutathione, 1-cysteine and dithiothreitol. A reduced compound of KF4939 (Red-KF4939) showed nearly equal anti-aggregating activities to those of KF4939 in PRP, it, however, showed low activities to inhibit platelet aggregation and thrombin -stimulated malondialdehyde production in washed platelet suspensions. In addition, the anti-aggregating action of Red-KF4939 was counteracted by pretreatment with sulfhydryl compounds, similarly to that of KF4939. Furthermore, when platelets were treated with KF4939, a significant decrease of protein-bound sulfhydryl groups was observed. We may conclude from these results that the intramolecular disulfide bond plays an essential role in anti-platelet actions of KF4939 and the interaction of the disulfide bond with protein-bound sulfhydryl groups may be involved in the mechanism of anti-platelet actions of KF4939.

Animals↗

Interaction of 5-hydroxytryptamine and ketanserin in rat vas deferens subjected to low frequency field stimulation.

The interaction of 5-hydroxytryptamine (5HT) and ketanserin was investigated in isolated rat vas deferens. Ketanserin (10(-7) M) almost completely abolished the phasic and the following rhythmic contractions induced by 5HT, whereas the inhibition by prazosin (10(-6) M) or methysergide (10(-6) M) of 5HT-induced contractions were incomplete. The amplitude of twitch contractions of vas deferens subjected to low frequency (0.1 Hz) field stimulation were substantially unchanged by 5HT (10(-7)-10(-5) M) per se. After pretreatment of the tissue with ketanserin (10(-8)-10(-6) M), 5HT, in a concentration-dependent manner, attenuated the amplitude of twitch contractions. Such attenuation of the amplitude was not observed after pretreatments with methysergide (10(-8)-10(-6) M) or prazosin (10(-7)-10(-5) M). The 5HT-induced inhibition of twitch contractions in the presence of ketanserin was not antagonized by phentolamine, propranolol, methysergide, morphine, promethazine, cimetidine, atropine or indomethacin. It is suggested that 5HT has dual (excitatory and inhibitory) effects upon nerve transmission of rat vas deferens, and only the excitatory effect is suppressed by ketanserin.

Animals↗

Inhibitory effects of oxatomide on several activities of SRS-A and synthetic leukotrienes in guinea-pigs and rats.

Effects of oxatomide, an orally active anti-allergic drug, on several activities of slow reacting substance of anaphylaxis (SRS-A) and synthetic leukotrienes (LT) C4, D4 and E4 were investigated. In addition, such activities of oxatomide were compared with those of FPL-55712. Oxatomide, at a concentration of 3 X 10(-8) M or higher, inhibited the phasic contractions of isolated guinea-pig ileum induced by partially purified SRS-Agp and SRS-Arat which were anaphylactically generated from guinea-pig lung fragments and rat peritoneal cavities, respectively. The 50% inhibitory concentrations (IC 50) of oxatomide to the contractions by SRS-Agp and SRS-Arat are 2.7 +/- 0.9 X 10(-7) M and 1.6 +/- 0.3 X 10(-7) M, respectively. Oxatomide also inhibited the LTC4, LTD4, histamine or serotonin-induced contractions of ileum. FPL-55712, a specific SRS-A antagonist, inhibited SRS-Agp, SRS-Arat, LTC4 or LTD4-induced contractions at concentrations ranging from 10(-9) M to 10(-6) M without affecting histamine and serotonin responses. Oxatomide produced dose-dependent relaxations of isolated guinea-pig tracheal and lung parenchymal strips precontracted with LTD4 and histamine. Oxatomide, at doses 10 and 30 mg/kg (p.o.), inhibited significantly the increase in vascular permeability produced by LTC4, LTE4, histamine and serotonin in rats. These results suggest that, although less effective and less selective as compared with FPL-55712, oxatomide exerts inhibitory effects on SRS-A activities, and that such effects could partly explain the anti-allergic effects of the compound.

Animals↗